MedTrace Logo

Study to Compare Safety and Pharmacokinetics of "CG1801" and "CGL1802" in Healthy Volunteers

NCT03774355 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-09-25

No results posted yet for this study

Summary

The objective of this open-label, randomized, 2\*2 crossover study is to compare the safety and Pharmacokinetics CG1801 and CGL1802 in Healthy Volunteers.

Conditions

  • Healthy

Interventions

DRUG

CG1801

Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.

DRUG

CGL1802

Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2

Sponsors & Collaborators

  • CrystalGenomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2019-05-03
Completion
2019-05-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774355 on ClinicalTrials.gov